[DataNet]
USCarePharm, a leading company specialized in the research and development of functional natural ingredients, announced that it has filed a PCT (Patent Cooperation Treaty) international patent application for the use of Salvia miltiorrhiza (Danshen) and Paeonia lactiflora (Peony) extracts in improving lipid metabolism disorders.

The company plans to expand the patent into more than 10 countries, including the United States and several European nations, as part of its global IP and market entry strategy.

The PCT international patent system allows applicants to streamline the filing process by submitting a single application to seek patent protection in 153 member countries. It also provides extended time (up to 30 months from the domestic filing date) to file in individual countries and ensures international recognition through early publication.

This patent application is based on UMAP (USCarePharm Material Advancement Platform)—the company’s proprietary technology for enhancing the bioavailability and efficacy of natural compounds. The formulation has demonstrated a wide range of effects, including:

Lowering blood triglyceride and cholesterol levels

Inhibiting adipocyte differentiation
Improving fatty liver symptoms
Reducing visceral fat accumulation
A USCarePharm official stated:

“In addition to Salvia and Paeonia, we hold multiple functional natural materials developed through UMAP. We are committed to expanding our IP and R&D pipelines, and this PCT application represents a significant step toward global expansion.”

USCarePharm continues to channel its UMAP-derived ingredients into high-performance cosmetic development, including its flagship functional derma-cosmetics brand LLEAFILL®.

LLEAFILL products are available through the official online store and across both domestic and international distributors and e-commerce platforms.

Source: DataNet
© DataNet. Unauthorized reproduction or redistribution is prohibited.